NCT04708860
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be initiating endocrine therapy in combination with palbociclib/Ibrance or alpelisib/Piqray
Exclusions: Patients with a diagnosis of diabetes that requires medication
https://ClinicalTrials.gov/show/NCT04708860